Clinical trials
Multiple System Atrophy clinical trials
Below are recruiting multiple system atrophy clinical trials, each written for real people, not researchers. We’re tracking 61 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07197866RecruitingPhase 2
Extension study of TEV-56286 for multiple system atrophy
This trial tests whether the drug TEV-56286 continues to work for multiple system atrophy (a rare brain disorder). It is for people who already completed a previous study of the same drug.
La Jolla, CaliforniaAges 30 years+ - NCT07289477RecruitingPhase 1
Study of NouvNeu001 for Multiple System Atrophy
This study tests a new injection called NouvNeu001 for people with Multiple System Atrophy (MSA). The goal is to see if it can help control symptoms that standard treatments aren't managing well.
Beijing, Beijing MunicipalityAges 30–70 - NCT06821256Recruiting
Testing brain stimulation for multiple system atrophy
This trial tests if a gentle electrical current applied to the scalp can help people with a specific type of multiple system atrophy (the cerebellar variant) improve walking and other symptoms. The goal is to see if this non-invasive treatment is safe and effective.
Salerno, SaAges 40–90 - NCT06568237RecruitingPhase 2
Testing TEV-56286 for Multiple System Atrophy
This trial tests a new drug called TEV-56286 for people with Multiple System Atrophy (MSA), a rare brain disorder. It aims to see if the drug can help control symptoms and slow the disease.
La Jolla, CaliforniaAges 30–75 - NCT03811808Recruiting
Multidisciplinary clinic visits for multiple system atrophy care
This study involves people with possible or probable multiple system atrophy (MSA) joining a specialized clinic team and attending visits every 4 months. It’s meant to improve care planning and support by bringing different specialists together.
Dallas, TexasAges 18 years+ - NCT04165486RecruitingPhase 1
Test drug safety in adults with multiple system atrophy
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
InnsbruckAges 40–70 - NCT04250493Recruiting
Testing insulin resistance in multiple system atrophy
This study looks at how the body handles blood sugar (insulin resistance) in people with multiple system atrophy (MSA). Results may help doctors understand the disease better and explore new ways to monitor or treat it.
BordeauxAges 30 years+ - NCT05121012Recruiting
PET brain scan study for synaptic loss in MSA or PSP
This study uses brain scans (PET, and possibly spinal fluid) to measure changes linked to “synaptic loss” in people with multiple system atrophy (MSA) or progressive supranuclear palsy (PSP). It may help researchers understand disease changes and how they relate to symptoms, which could guide future treatments.
ExeterAges 45–80 - NCT06072105Recruiting
Medical decisions in multiple system atrophy: a study in Austria
This study looks at how medical decisions are made for people with multiple system atrophy (MSA). It includes both people with MSA and their unpaid caregivers who live in Austria and speak German. Participants and caregivers will share their experiences through online interviews to help improve future care.
Innsbruck, AustriaAges 30 years+ - NCT06203106Recruiting
NYSCF Scientific Discovery Biobank
This study collects blood, saliva, or skin samples from people with certain neurological conditions and from healthy volunteers to help researchers better understand and find treatments for these diseases.
New York, New YorkAges 4 weeks+ - NCT06647641Recruiting
Genetics study for PSP, CBS, MSA, and related conditions
This study looks at genetic factors in people with PSP, CBS, MSA, or similar brain conditions, and also in their family members. It involves genetic testing to learn more about these diseases and may help find new treatments.
Boston, MassachusettsAges 35 years+ - NCT06765733RecruitingEarly Phase 1
Testing Aleeto for multiple system atrophy (MSA)
This trial tests a new treatment called Aleeto for people with a specific type of multiple system atrophy (MSA-P) who haven't responded well to standard Parkinson's medications. The goal is to see if Aleeto is safe and might help improve symptoms.
Beijing, Beijing MunicipalityAges 30–75 - NCT06831500RecruitingPhase 1/Phase 2
Study on carbidopa/levodopa ratio for low blood pressure in MSA-P and Parkinson's
This study tests whether adjusting the ratio of carbidopa and levodopa (medications used for Parkinson's) can help reduce dizziness or fainting from low blood pressure when standing up, in people with Multiple System Atrophy (Parkinsonian type) or Parkinson's disease.
Lausanne, Canton of VaudAges Any age - NCT06848231RecruitingPhase 2
Study of YA-101 for multiple system atrophy
This trial tests if a new oral medication, YA-101, can help people with multiple system atrophy (MSA), a rare brain condition. It aims to see if the drug is safe and works for both types of MSA (parkinsonian and cerebellar).
Los Angeles, CaliforniaAges 30 years+ - NCT06868628RecruitingPhase 2
Nasal spray for multiple system atrophy (MSA) study
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
Boston, MassachusettsAges 30–85 - NCT06920134Recruiting
Spinal cord stimulation for blood pressure in Parkinson's disease
This trial tests if electrical stimulation of the spinal cord can help manage blood pressure drops (orthostatic hypotension) in people with Parkinson's and related conditions. It might make daily activities like standing and walking easier.
Lausanne, Canton of VaudAges 18–90 - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT02795052Recruiting
Stem cell treatment trial for nerve injury
This study tests whether bone-marrow stem cells can improve nerve function in people with nerve damage that usually doesn’t recover with current care. It also checks whether the treatment is safe and whether people can be followed over time with repeated nerve exams.
Westport, ConnecticutAges 18 years+ - NCT07446894RecruitingPhase 3
Testing MSA-01 for multiple system atrophy
This phase 3 trial tests a new oral drug (MSA-01) for people with multiple system atrophy. It aims to see if the drug can slow disease progression and improve daily function.
Nagoya, Aichi-kenAges 30–79 - NCT07467187Recruiting
Home Ventilation with Tracheostomy in Denmark (2016–2025)
This study looks at people in Denmark who need a home ventilator through a tracheostomy. It aims to understand their care and outcomes over several years.
CopenhagenAges Any age - NCT07644013Recruiting
Multiple System Atrophy Registry Study in China
This study is collecting information from patients with multiple system atrophy (a rare neurological condition affecting movement and body functions), Parkinson disease, and healthy volunteers to better understand these conditions. By participating, you help doctors learn more about how these diseases develop and progress.
Beijing, Beijing MunicipalityAges 40–75 - NCT06745011Enrolling by invitation
Parkinson's signs in people with nerve damage
This study looks for early signs of Parkinson's disease in people who have nerve damage in their hands and feet (polyneuropathy) with no known cause, along with drops in blood pressure when standing up. It aims to understand if these early symptoms might predict future Parkinson's.
Aarhus, JutlandAges 18–85 - NCT02194816Recruiting
Online survey study for people with Parkinson’s or Parkinsonism
This study looks at how changing certain factors over time relates to symptoms in Parkinson’s disease and related conditions. You may help researchers by completing longer online surveys every 6 months for 5 years.
Kenmore, WashingtonAges 19 years+ - NCT07640542RecruitingEarly Phase 1
Brain imaging study for Parkinson's and MSA patients
This early-stage research trial tests a new brain-imaging tracer called [11C]MODAG-005 to help doctors better understand Parkinson's disease (PD) and multiple system atrophy (MSA). You would undergo PET/CT and MRI scans twice, a few weeks apart, to see how reliable the imaging is.
Tübingen, Baden-WurttembergAges 50–75
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Multiple System Atrophy trials by city
Studies with a site in or near these metro areas.
Multiple System Atrophy trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for multiple system atrophy?
- Yes. Clin2 currently lists 61 recruiting multiple system atrophy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple system atrophy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple system atrophy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.